Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30784348 | 0.96 | AKT1 (0.47) | AKT1AKT2AKT3CRHR1PIK3CB | |
| SCHEMBL30783583 | 0.96 | AKT1 (0.47) | AKT1AKT2AKT3CRHR1PIK3CB | |
| SCHEMBL30784055 | 0.90 | AKT1 (0.48) | AKT1AKT2AKT3CRHR1HTT | |
| SCHEMBL30784529 | 0.88 | AKT1 (0.41) | AKT1AKT2AKT3CRHR1PIK3CB | |
| SCHEMBL30783939 | 0.87 | PIK3CB (0.40) | AKT1AKT2AKT3PIK3CBPIK3CA | |
| SCHEMBL27305600 | 0.87 | AKT1 (0.48) | AKT1AKT2AKT3PIK3CBHTT | |
| SCHEMBL30784330 | 0.85 | AKT1 (0.47) | AKT1AKT2AKT3CRHR1PIK3CB | |
| SCHEMBL30783993 | 0.85 | AKT1 (0.49) | AKT1AKT2AKT3CRHR1PIK3CB | |
| SCHEMBL30783794 | 0.85 | HTT (0.40) | AKT1AKT2AKT3HTTPIK3CA | |
| SCHEMBL30784536 | 0.84 | AKT1 (0.43) | AKT1AKT2AKT3CRHR1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026424-A1 | QUINAZOLINONE DERIVATIVES AS AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |